Cross‐Sectional Analysis of Research and Non‐Research Payments From the Medical Device Industry to Healthcare Professionals and Organisations in Japan in 2022
Journal of Evaluation in Clinical Practice,
Journal Year:
2025,
Volume and Issue:
31(2)
Published: March 1, 2025
ABSTRACT
Rationale
Financial
relationships
between
healthcare
professionals
(HCPs),
organisations
(HCOs)
and
the
medical
device
industry
in
Japan
may
lead
to
conflicts
of
interest.
Limited
transparency
these
has
raised
concerns
regarding
their
potential
influence
on
clinical
decision‐making
patient
care.
Aims
Objectives
This
study
aimed
assess
scope
magnitude
financial
payments
from
companies
HCPs
HCOs
Japan,
focusing
publicly
disclosed
data
2022
fiscal
year.
Methods
A
cross‐sectional
analysis
available
payment
disclosures
169
companies,
including
all
members
Federation
Medical
Devices
Associations
(JFMDA)
several
major
non‐JFMDA
affiliated
was
conducted.
Descriptive
statistics
were
calculated
summarise
data.
Results
Of
32.5%
(55
companies)
did
not
disclose
information
6
records
aggregated
amounts
with
group
leaving
108
for
analysis.
In
total,
$245.2
million
made
2022,
only
23.9%
($58.7
million)
research
development.
34.6%
($84.9
allocated
non‐research
sponsoring
HCOs’
activities,
19.6%
($49.0
paid
lecturing
consulting
fees,
typically
individual
HCPs.
More
than
80%
a
greater
share
activities
research.
Conclusion
reveals
substantial
HCPs/HCOs
predominantly
purposes.
Improved
regulations,
uniform,
government‐run
database,
are
necessary
better
oversee
interactions
Japan.
Language: Английский
Pharmaceutical company payments to Japanese breast cancer practice guideline authors
Clinical and Translational Discovery,
Journal Year:
2024,
Volume and Issue:
4(3)
Published: June 1, 2024
Abstract
Background
The
creation
of
breast
cancer
practice
guidelines
requires
proper
management
financial
relationships
with
drug
companies,
as
they
can
introduce
conflicts
interest
(COIs)
among
guideline
authors.
However,
little
is
known
about
the
specific
landscape
and
fraction
interactions
between
authors
Japanese
Breast
Cancer
Society
Clinical
Practice
Guidelines
for
Cancer,
edition
2022
(JBCS2022)
companies.
Methods
Using
payment
data
publicly
disclosed
by
major
companies
in
Japan,
this
study
analysed
personal
payments
made
to
JBCS2022
2016
2020.
We
performed
descriptive
analyses
on
data.
Results
Of
149
authors,
115
(77.2%)
received
at
least
one
totaling
$3
828
455
from
average
median
amounts
per
author
were
$25
772
(standard
deviation:
$58
197)
$2761
(interquartile
range:
$322‒$15
828),
respectively.
total
annual
2019
increased
$588
054
$967
802
2019.
chairperson
vice‐chairperson
$246
936
(fourth
highest)
$216
744
(fifth
over
5
years.
More
than
60%
not
declared
below
declaration
threshold
set
Society.
nine
undeclared
summing
$594
615
even
though
these
higher
thresholds.
Conclusion
This
demonstrated
that
majority
Japan.
Furthermore,
because
less
transparent
COI
policy.
Language: Английский
Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan
BMJ Open,
Journal Year:
2024,
Volume and Issue:
14(6), P. e086396 - e086396
Published: June 1, 2024
Objective
Clinical
practice
guidelines
(CPGs)
are
essential
for
standardising
patient
care
based
on
evidence-based
medicine.
However,
the
presence
of
financial
conflicts
interest
(COIs)
among
CPG
authors
can
undermine
their
credibility.
This
study
aimed
to
examine
extent
and
size
COIs
psychiatry
CPGs
in
Japan.
Methods
cross-sectional
analysis
disclosed
payments
from
pharmaceutical
companies
assesses
prevalence
magnitude
personal
lecturing,
consulting
writing
bipolar
disorder
major
depressive
Japan
between
2016
2020.
Results
found
that
93.3%
received
over
a
5-year
period,
with
total
exceeding
US$4
million.
The
median
payment
per
author
was
US$51
403
(IQR:
US$9982–US$111
567),
notable
concentration
small
number
authors,
including
chairperson.
Despite
these
extensive
relationships,
only
fraction
CPGs.
These
large
amounts
were
made
by
manufacturing
new
antidepressants
sleeping
aids
listed
Conclusions
more
than
93%
considerable
industry.
findings
highlight
deviations
international
COI
management
standards
suggest
need
stringent
policies
Language: Английский
Non-research payments to board-certified cardiologists from pharmaceutical industry in Japan from 2016 to 2019: a retrospective analysis
BMJ Open,
Journal Year:
2024,
Volume and Issue:
14(7), P. e083445 - e083445
Published: July 1, 2024
Objectives
To
evaluate
the
extent
and
trends
of
personal
payments
from
pharmaceutical
companies
to
cardiologists
board-certified
by
Japanese
Circulation
Society.
Design
A
retrospective
analysis
study
using
data
a
publicly
available
database.
Setting
The
focused
on
in
Japan.
Participants
All
15
048
who
were
Society
as
2021.
Primary
secondary
outcome
measures
primary
was
2016–19.
Secondary
outcomes
included
these
over
same
period.
Results
Of
all
cardiologists,
9858
(65.5%)
received
totaling
$112
934
503
entailing
165
013
transactions
median
payment
per
cardiologist
$2947
(IQR,
$1022–$8787),
with
mean
$11
456
(SD,
$35
876).
Gini
Index
0.840,
indicating
high
concentration
small
number
cardiologists.
top
1%,
5%
10%
31.6%,
59.4%
73.5%
payments,
respectively.
There
no
significant
receiving
or
during
Conclusions
More
than
65%
4-year
Although
amount
relatively
for
majority
vast
payments.
Language: Английский
Pharmaceutical industry payments to authors of neurology clinical practice guidelines in Japan: A cross‐sectional study
Health Science Reports,
Journal Year:
2024,
Volume and Issue:
7(9)
Published: Sept. 1, 2024
Language: Английский
Financial conflicts of interest among authors of clinical practice guideline for headache disorders in Japan
BMC Medical Ethics,
Journal Year:
2024,
Volume and Issue:
25(1)
Published: Oct. 29, 2024
Financial
relationships
between
clinical
guideline
authors
and
pharmaceutical
companies
introduce
conflicts
of
interest
(COI),
potentially
biasing
recommendations.
Thus,
proper
management
COI
is
paramount
for
authors.
Nevertheless,
little
known
about
among
neurology
This
study
aimed
to
evaluate
the
financial
Clinical
Practice
Guideline
Headache
Disorders
(CPGHD)
in
Japan.
a
retrospective
analysis
2016–2020
personal
payments
data
disclosed
by
all
affiliated
with
Japan
Pharmaceutical
Manufacturers
Association.
We
examined
amounts
fraction
57
CPGHD
neurologists
board-certified
Japanese
Society
Neurology.
Payment
was
descriptively
analyzed
at
individual
author
level.
Among
authors,
56
(98.3%)
received
totaling
$2.7
million
from
2016
2020.
Median
five-year
were
$89,955
while
$521
neurologists.
The
chairperson
vice
substantial
during
development
period.
because
less
rigorous
transparent
policy
compared
international
standard
policies,
only
10
their
guideline.
More
than
98%
much
higher
those
period
Language: Английский